Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34762097.
- Also identified by DOI 10.1001/jamaoncol.2021.5433 and PMC identifier 8587215.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cross-sectional study examines patients’ out-of-pocket costs with and without rebate pass-through to point-of-sale prices for cancer drugs under Medicare Part D.
Medical subject headings
- Antineoplastic Agents
- Drug Costs
- Medicare Part D
- Neoplasms